The FDA has officially rescinded the 2025 final rule on laboratory-developed tests (LDTs), restoring previous regulatory oversight that does not explicitly extend FDA authority over LDTs. This policy reversal affects oversight of in vitro diagnostics, with significant implications for diagnostic developers, clinical laboratories, and healthcare stakeholders. The agency's decision responds to ongoing debates about regulation balance, innovation, and patient safety in diagnostics.